Cargando…

De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents

AIM: Recent studies raise concerns for higher incidence of hepatocellular carcinoma (HCC) after direct-acting antiviral therapy for hepatitis C virus (HCV). METHODS: In this study, using analysis of liver imaging pre- and post-DAA treatment, we queried new occurrence or ‘de novo’ of HCC in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuftinec, Gabriela, Loehfelm, Thomas, Corwin, Michael, Durbin-Johnson, Blythe, Candido, MarieChristi, Hluhanich, Rebecca, Sarkar, Souvik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168046/ https://www.ncbi.nlm.nih.gov/pubmed/30302197 http://dx.doi.org/10.2217/hep-2018-0003

Ejemplares similares

Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents
por: Mathur, Karan, et al.
Publicado: (2021)

Non-alcoholic Fatty Liver Disease in South Asians: A Review of the Literature
por: Singh, Sital, et al.
Publicado: (2017)

Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed
por: Hassany, Sahar M, et al.
Publicado: (2020)

Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?
por: Butt, Amna Subhan, et al.
Publicado: (2018)

Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals
por: Syed, Taseen, et al.
Publicado: (2018)

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
por: Kamal, Ahmed, et al.
Publicado: (2022)

Enlargement of the Spleen Index Is a Predictor of the Occurrence of Esophageal Varices and Hepatocellular Carcinoma after Administering Direct-acting Antiviral Agents
por: Furuichi, Yoshihiro, et al.
Publicado: (2023)

The Complex Interplay Relationship between HCV Infection, Direct-Acting Antiviral Therapy, and Hepatocellular Carcinoma Occurrence
por: Cavalletto, Luisa, et al.
Publicado: (2023)

Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort)
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2020)

Antiviral therapy of HCV in the cirrhotic and transplant candidate
por: Herrine, Steven K., et al.
Publicado: (2006)

Antiviral Therapy in HCV-infected Decompensated Cirrhotics
por: Danish, Fazal A., et al.
Publicado: (2010)

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
por: Kishta, Sara, et al.
Publicado: (2020)

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C
por: Kawagishi, Naoki, et al.
Publicado: (2023)

Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
por: Kim, David Sooik, et al.
Publicado: (2021)

Hepatocellular Carcinoma and Associated Clinical Features in Latino and Caucasian Patients from a Single Center
por: Kuftinec, Gabriela N., et al.
Publicado: (2019)

A new model to predict response to direct-acting antiviral therapy in decompensated cirrhotics due to hepatitis C virus
por: Debnath, Prasanta, et al.
Publicado: (2020)

Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues
por: Tampaki, Maria, et al.
Publicado: (2018)

Frequency of De Novo Hepatocellular Carcinoma after Direct-acting Antiviral Therapy for Chronic Hepatitis C: A Prospective Follow-up
por: Rasool, Shahid, et al.
Publicado: (2022)

Clinicopathological and prognostic significance of PKM2 protein expression in cirrhotic hepatocellular carcinoma and non-cirrhotic hepatocellular carcinoma
por: Liu, Yan, et al.
Publicado: (2017)

Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients
por: Liang, Kung-Hao, et al.
Publicado: (2021)

Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?
por: Huang, Chung-Feng, et al.
Publicado: (2019)

Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C
por: Hayashi, Takeo, et al.
Publicado: (2016)

Improved on-treatment fibrosis-4 during antiviral therapy and lower hepatocellular carcinoma risk in cirrhotic patients with hepatitis B
por: Oh, Joo Hyun, et al.
Publicado: (2023)

Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response
por: Itami-Matsumoto, Saori, et al.
Publicado: (2019)

Comparing Hepatitis C Virus Screening in Clinics Versus the Emergency Department
por: Hluhanich, Rebecca, et al.
Publicado: (2022)

Usage of Direct Acting Oral Anticoagulants in Cirrhotic and Non-Cirrhotic Portal Vein Thrombosis: A Systematic Review
por: Gupta, Sachin, et al.
Publicado: (2021)

Hepatocellular Carcinoma Arising in Non-Cirrhotic Haemochromatosis
por: Thompson, N. P., et al.
Publicado: (1995)

Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers
por: Renzulli, Matteo, et al.
Publicado: (2022)

Long-acting antiviral agents for HIV treatment
por: Margolis, David A., et al.
Publicado: (2015)

Baicalein reduces the occurrence of cirrhotic endotoxemia by reducing intestinal mucosal apoptosis
por: Liu, Yi, et al.
Publicado: (2015)

Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma
por: Lin, Wei-Chen, et al.
Publicado: (2020)

Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals
por: Cabral, Loraine Kay D., et al.
Publicado: (2022)

Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
por: Tajiri, Kazuto, et al.
Publicado: (2022)

Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma
por: Zanetto, Alberto, et al.
Publicado: (2018)

Digital pancreatoscopy with electrohydraulic lithotripsy to treat a pancreatic duct stone
por: Kuftinec, Gabriela, et al.
Publicado: (2017)

Tolloid-like 1 gene variant rs17047200, pretreatment FIB-4, ALBI and PALBI scores as predictors of hepatocellular carcinoma occurrence after directly acting antivirals
por: Kamal, Ahmed, et al.
Publicado: (2022)

Two Cases of Hepatocellular Carcinoma Occurring Immediately after Direct-acting Antiviral Agents against Hepatitis C Virus
por: Nishijima, Norihiro, et al.
Publicado: (2018)

Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents
por: Chen, Qiushi, et al.
Publicado: (2020)

Deveopment of hepatocellular carcinoma in a non-cirrhotic, long-term responder to antiviral therapy, chronic hepatitis C patient: what kind of surveillance?
por: Bertolini, Elena, et al.
Publicado: (2013)

Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals
por: Schietroma, Ivan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_amk5man5naqjt0vhknrtil0dph